Back to top
more

Axovant Sciences Ltd. (AXGT)

(Delayed Data from NSDQ)

$1.13 USD

1.13
670,149

-0.01 (-0.44%)

Updated May 3, 2019 04:00 PM ET

After-Market: $1.13 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.57%
2Buy19.14%
3Hold10.74%
4Sell6.46%
5Strong Sell3.16%
S&P50011.27%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Zacks News

Axovant's Gene Therapy Gets Rare Pediatric Disease Status

The FDA bestows a Rare Pediatric Disease status on Axovant's (AXGT) gene therapy candidate AXO-AAV-GM1, which is being developed for the treatment of GM1 gangliosidosis. Stock appreciates.

Do Options Traders Know Something About Axovant (AXGT) Stock We Don't?

Investors need to pay close attention to Axovant (AXGT) stock based on the movements in the options market lately.

Axovant (AXGT) Catches Eye: Stock Jumps 12%

Axovant (AXGT) saw a big move last session, as its shares jumped nearly 12% on the day, amid huge volumes.

Why Axovant Gene Therapies (AXGT) Stock Might be a Great Pick

Axovant Gene Therapies (AXGT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Dynavax Closes Enrollment in Renal Disease Study on Heplisav-B

Dynavax (DVAX) is developing its hepatitis B vaccine, Heplisav-B, in patients with end-stage renal disease undergoing hemodialysis in a phase I study.

Axovant (AXGT) Moves to Strong Buy: Rationale Behind the Upgrade

Axovant (AXGT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Will Ventilator Sales Drive Medtronic's (MDT) Q4 Earnings?

Medtronic (MDT) might have registered lower demand for its emergency procedures in Q4 with patients trying to avoid any non-COVID-19 emergency treatment.

CytoDyn (CYDY) to Report Q4 Earnings: What's in the Cards?

On CytoDyn's (CYDY) upcoming earnings call, investor focus will be on the updates related to its CCR5 antagonist candidate, leronlimab, which is being developed for multiple therapeutic indications.

Top Ranked Momentum Stocks to Buy for May 5th

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, May 5th

All You Need to Know About Axovant (AXGT) Rating Upgrade to Buy

Axovant (AXGT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes Axovant (AXGT) a New Buy Stock

Axovant (AXGT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Axovant's GM1 Gangliosidosis Candidate Gets Orphan Drug Tag

The FDA grants Orphan Drug status to Axovant's (AXGT) gene therapy candidate, AXO-AAV-GM1, being developed for the treatment of GM1 gangliosidosis. Shares decline despite the positive news.

Axovant Gene Therapies Enters Oversold Territory

Axovant Gene Therapies has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Axovant (AXGT) Moves to Strong Buy: Rationale Behind the Upgrade

Axovant (AXGT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Axovant (AXGT) Upgraded to Buy: Here's What You Should Know

Axovant (AXGT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Axovant (AXGT) Gains As Market Dips: What You Should Know

In the latest trading session, Axovant (AXGT) closed at $6.61, marking a +0.46% move from the previous day.

Axovant (AXGT) Stock Moves -1.31%: What You Should Know

Axovant (AXGT) closed at $7.53 in the latest trading session, marking a -1.31% move from the prior day.

Axovant (AXGT) Gains As Market Dips: What You Should Know

Axovant (AXGT) closed at $7.69 in the latest trading session, marking a +0.92% move from the prior day.

Immunomedics (IMMU) Posts Wider-Than-Expected Loss in Q2

Immunomedics (IMMU) posts wider-than-expected loss and generates no revenues in the second quarter of 2019.

Horizon Therapeutics' (HZNP) Q2 Earnings Beat Estimates

Horizon (HZNP) beats earnings and sales estimates in the second quarter of 2019.

Catalyst's (CPRX) Q2 Earnings and Revenues Beat Estimates

Catalyst (CPRX) surpasses earnings and sales estimates in the second quarter of 2019.

Geron (GERN) Stock Up Despite Q2 Earnings & Sales Miss

Geron (GERN) posts a wider-than-expected loss in second-quarter 2019. Operating expenses increase on a year-over-year basis.

IVERIC bio's (ISEE) Q2 Loss Narrows, Gene Therapy in Focus

IVERIC bio (ISEE) second-quarter earnings improve year over year. The company is focusing on developing gene therapies for treating inherited retinal diseases.

Clovis (CLVS) Q2 Earnings & Sales Lag Estimates, Shares Down

Clovis (CLVS) reports dismal second-quarter 2019 results. The company provides lower-than-expected guidance for product sales in 2019.

Axovant (AXGT) Gains As Market Dips: What You Should Know

Axovant (AXGT) closed at $6.67 in the latest trading session, marking a +1.52% move from the prior day.